The Pasteur Museum is housed in the apartment where Louis Pasteur spent his final seven years and offers a rare behind-the-scenes look at the living and working environment of the world-renowned scientist. Visitors can gain a unique insight into his everyday life alongside his wife and can admire his rich and diverse scientific work.
The Institut Pasteur’s scientific strategy focuses on developing original and innovative topics and promoting interdisciplinary and multidisciplinary cooperation and approaches. The Institut Pasteur teams have access to the technological resources needed to speed up and further improve the quality of their outstanding research.
Ever since the introduction of the world’s first "Technical Microbiology" course in 1889, teaching has been a priority for the Institut Pasteur. The Institut Pasteur has an international reputation for quality teaching that attracts students from all over the world who come to further their training or top up their degree programs.
The mission of the Industrial Partnership team is to detect, promote, assist and protect the inventive activities from research (inventions, know-how and biological materials) conducted at the Institut Pasteur (and in some Institutes of its international network), and transfer there to industrial and/or institutional partners, in order to serve the patient needs and for the benefit of the society, as well as to contribute to sustainability of the Institut Pasteur’s resources.
With international courses, PhD and postdoctoral traineeship, each institute of the Institut Pasteur International Network (RIIP) contributes to the transmission of knowledge with the training of young researchers all around the world. In this context, doctoral and postdoctoral programmes, study and traineeship fellowships are available to scientists. Alongside training, dynamism and attractiveness of RIIP will result in the creation of 4-year group for the young researchers.
Using pathogenic fungi to develop anti-inflammatory treatments
Scientists at the Institut Pasteur, Radboudumc university medical center (The Netherlands), and the University of Perugia (Italy), recently identified the mechanism by which a component of the cell wall of the pathogenic fungus Aspergillus fumigatus triggers an anti-inflammatory effect. They then showed that this same component could be used as a potential treatment for various inflammatory diseases. Their work also opens up new avenues of research for the development of therapeutic solutions to combat invasive, and often fatal, aspergillosis. This work was published march 6, 2014 in the medical journal PLoS Pathogens.
Paris, March 7, 2014
Aspergillus fumigatus is an airborne fungus that causes respiratory infections in humans. It is responsible for the majority of cases of invasive aspergillosis, the second leading cause of fungal infection-related death in hospitals. Patients with weakened immune systems are at particularly high risk of contracting the infection.
Recently, the Aspergillus Unit at the Institut Pasteur, led by Jean-Paul Latgé, identified an Aspergillus fumigatus molecule with powerful anti-inflammatory properties. The molecule, galactosaminogalactan or GAG, is a polysaccharide (sugar polymer) found in the fungus' cell wall.
In this new study, the Institut Pasteur team in collaboration with an italian team led by Luigina Romani and a dutch team led by Frank van de Veerdonk, precisely describes, both in mice models and in vitro using several human immune system cells, the action mechanism of the GAG polysaccharide that triggers this anti-inflammatory effect.
The scientists showed that the GAG polysaccharide inhibits the activities of interleukin 1 (IL-1), a major molecule responsible for activating the immune system when attacked by a pathogenic agent. It does this by synthesizing a protein that effectively replaces IL-1 on its receptor. This protein, called IL1-RA (IL1 receptor antagonist), prevents IL-1 from sending its signal to cells involved in the body’s defense mechanism. They also showed that mice lacking IL1-RA are resistant to invasive aspergillosis, which opens up new avenues of research for the development of treatments to combat invasive aspergillosis through the targeting of IL1-RA.
In addition, using colitis (inflammation of the colon) as an experimental model, the scientists observed that they could cure inflammation by administering the GAG polysaccharide. This leads them to believe that the molecule’s anti-inflammatory properties might also be used to treat inflammatory and auto-immune diseases involving IL-1, notably gout and rheumatoid arthritis.
A polysaccharide virulence factor from Aspergillus fumigatus elicits anti-inflammatory effects through induction of interleukin-1 receptor antagonist, PLoS Pathogens, 6 mars 2014.
Mark S. Gresnigt (1,2), Silvia Bozza (3), Katharina L. Becker (1,2), Leo A. B. Joosten (1,2) , Shahla Abdollahi-Roodsaz (2,4), Wim B. van der Berg (2,4), Charles A. Dinarello (1,5), Mihai G. Netea (1,2), Thierry Fontaine (6), Antonella De Luca (3), Silvia Moretti (3), Luigina Romani (3), Jean-Paul Latge (6), Frank L. van de Veerdonk (1,2)
(1) Department of Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
(2) Institute for Infection, Inflammation, and Immunity (N4i), Nijmegen, The Netherlands
(3) Microbiology Section, Department of Experimental Medicine and Biochemical Sciences,
University of Perugia, Perugia, Italy
(4) Department of Rheumatology, Radboud University Medical Center, Nijmegen, The
(5) Department of Medicine, University of Colorado Denver, Aurora, CO, USA
(6) Unité des Aspergillus, Institut Pasteur, Paris, France